RUXOLITINIB



Jakavi


Indication:


It is used in the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow, and for polycythemia vera (PCV) when there has been an inadequate response to or intolerance of hydroxyurea.



Brand name:Jakavi

Active Ingeridents: Ruxolitinib

Company Name: Novartis

Package: 14 tabs in strip

Strength : 5mg

Mechanism of action:


Jakavi (Ruxolitinib) is a Janus kinase inhibitor with selectivity for subtypes JAK1 and JAK2 of this enzyme. Jakavi (Ruxolitinib) inhibits dysregulated JAK signaling associated with myelofibrosis. JAK1 and JAK2 recruit signal transducers and activators of transcription (STATs) to cytokine receptors leading to modulation of gene expression.


Dosage and Administration:


Jakavi (Ruxolitinib ) is a pill, taken by mouth, with or without food. Take Jakavi (Ruxolitinib ) exactly as prescribed, even if you are feeling better. Swallow Jakavi (Ruxolitinib) tablets whole. Do not chew, crush or break.


Precaution:



  • Jakavi (Ruxolitinib) may interact with many types of medications. Before starting Jakavi (Ruxolitinib ) treatment, make sure you tell your doctor about any other medications you are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc.).
  • Do not receive any kind of immunization or vaccination without your doctor's approval while taking Jakavi (Ruxolitinib).
  • Inform your health care professional if you are pregnant or may be pregnant prior to starting this treatment. Pregnancy category C (use in pregnancy only when benefit to the mother outweighs risk to the fetus).

Side effects:


Side effects include thrombocytopenia (low blood platelet count), anemia (low red blood cell count) and neutropenia; risk of infection; symptom exacerbation if the medication is interrupted or discontinued; and non-melanoma skin cancer.


Immunologic side effects have included herpes zoster (shingles) and case reports of opportunistic infections. Metabolic side effects have included weight gain. Laboratory abnormalities have included alanine transaminase (ALT) abnormalities, aspartate transaminase (AST) abnormalities, and mildly elevated cholesterol levels.


Store:


Store Jakavi (Ruxolitinib) at room temperature, between 59o to 86oF (15o to 30o C)Store away from heat, moisture, and light.






WARNING:


Jakavi (Ruxolitinib) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.



Jakavi



Indication:

It is used in the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow, and for polycythemia vera (PCV) when there has been an inadequate response to or intolerance of hydroxyurea.



Brand name: Jakavi

Active Ingeridents:Melphalan

Company Name: Natco

Package: 25 Tablets

Strength :2mg

Mechanism of action:


Jakavi (Ruxolitinib) is a Janus kinase inhibitor with selectivity for subtypes JAK1 and JAK2 of this enzyme. Jakavi (Ruxolitinib ) inhibits dysregulated JAK signaling associated with myelofibrosis. JAK1 and JAK2 recruit signal transducers and activators of transcription (STATs) to cytokine receptors leading to modulation of gene expression.


Dosage and Administration:


Jakavi (Ruxolitinib ) is a pill, taken by mouth, with or without food. Take Jakavi (Ruxolitinib ) exactly as prescribed, even if you are feeling better. Swallow Jakavi (Ruxolitinib) tablets whole. Do not chew, crush or break.


Precaution:


  • Jakavi (Ruxolitinib ) may interact with many types of medications . Before starting Jakavi (Ruxolitinib) treatment, make sure you tell your doctor about any other medications you are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc.).
  • Do not receive any kind of immunization or vaccination without your doctor's approval while taking Jakavi (Ruxolitinib ).
  • Inform your health care professional if you are pregnant or may be pregnant prior to starting this treatment. Pregnancy category C (use in pregnancy only when benefit to the mother outweighs risk to the fetus).

Side effects:


Side effects include thrombocytopenia (low blood platelet count), anemia (low red blood cell count) and neutropenia; risk of infection; symptom exacerbation if the medication is interrupted or discontinued; and non-melanoma skin cancer.


Immunologic side effects have included herpes zoster (shingles) and case reports of opportunistic infections. Metabolic side effects have included weight gain. Laboratory abnormalities have included alanine transaminase (ALT) abnormalities, aspartate transaminase (AST) abnormalities, and mildly elevated cholesterol levels.


Store:


Store Jakavi (Ruxolitinib) at room temperature, between 59o and 86o F (15o and 30oC). Store away from heat, moisture, and light.



WARNING:


Jakavi (Ruxolitinib) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.